Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753856 | 0.92 | TSHR (0.49) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL18632964 | 0.92 | CYP3A4 (0.53) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL255503 | 0.92 | CYP3A4 (0.53) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL22958242 | 0.86 | TSHR (0.47) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL801167 | 0.85 | CYP3A4 (0.42) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL16579996 | 0.85 | USP2 (0.44) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL25207249 | 0.83 | USP2 (0.43) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL23299654 | 0.81 | TSHR (0.44) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL799975 | 0.79 | CYP3A4 (0.45) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL7711019 | 0.79 | CYP2D6 (0.50) | CYP2D6CYP3A4ALDH1A1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| EP-3885342-A1 | BICYCLIC INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| WO-2021163254-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2012031199-A1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | CYP2D6 1121/4885CYP3A4 1661/4885ALDH1A1 265/4885 |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | CYP2D6 1614/4885CYP3A4 2176/4885ALDH1A1 297/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | CYP2D6 4734/4885CYP3A4 4729/4885ALDH1A1 2808/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CYP2D6 3061/4885CYP3A4 2763/4885ALDH1A1 2293/4885 |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | CYP2D6 1124/4885CYP3A4 2057/4885ALDH1A1 2196/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | CYP2D6 2783/4885CYP3A4 2848/4885ALDH1A1 3532/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CYP2D6 588/4885CYP3A4 574/4885ALDH1A1 1643/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CYP2D6 477/4885CYP3A4 428/4885ALDH1A1 1393/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP2D6 1847/4885CYP3A4 2444/4885ALDH1A1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.